Discovery of N-benzyl-N'-(4-pipyridinyl)urea CCR5 antagonists as anti-HIV-1 agents (I): optimization of the amine portion.
Duan
Maosheng
M
Infectious Diseases Center for Excellence in Drug Discovery, GlaxoSmithKline, Research Triangle Park, NC 27709, USA. maosheng.a.duan@gsk.com
Peckham
Jennifer
J
Edelstein
Mark
M
Ferris
Robert
R
Kazmierski
Wieslaw M
WM
Spaltenstein
Andrew
A
Wheelan
Pat
P
Xiong
Zhiping
Z
D000588:Amines / Q000737:chemistry*; D000818:Animals; D019380:Anti-HIV Agents / Q000138:chemical synthesis / Q000737:chemistry* / Q000493:pharmacokinetics; D065100:CCR5 Receptor Antagonists; D045744:Cell Line, Tumor; D004353:Drug Evaluation, Preclinical; D015497:HIV-1 / Q000187:drug effects*; D006801:Humans; D010671:Phenylurea Compounds / Q000138:chemical synthesis / Q000737:chemistry* / Q000493:pharmacokinetics; D051381:Rats; D017207:Rats, Sprague-Dawley; D019713:Receptors, CCR5 / Q000378:metabolism; D013329:Structure-Activity Relationship; D013449:Sulfonamides / Q000138:chemical synthesis / Q000737:chemistry* / Q000493:pharmacokinetics; D014508:Urea / Q000031:analogs & derivatives* / Q000138:chemical synthesis / Q000493:pharmacokinetics; D014779:Virus Replication / Q000187:drug effects
D000588:Amines; D019380:Anti-HIV Agents; D065100:CCR5 Receptor Antagonists; D010671:Phenylurea Compounds; D019713:Receptors, CCR5; D013449:Sulfonamides; D014508:Urea